When was Talus founded?

Talus was founded in 2020 and raised its 1st funding round within a year of its incorporation.

Where is Talus located?

Talus is headquartered in Seattle, United States.

Who is the current CEO of Talus?

Alex Federation of Talus. They have also founded 2 companies.

How many employees does Talus have?

As of Aug 31, 2026, the latest employee count at Talus is 28.

Is Talus a funded company?

Talus is a funded company, having raised a total of $19.8M across 8 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on 2020.

How much is Talus worth?

The latest valuation of Talus is $***** as of Feb 01, 2024.

When was the latest funding round of Talus?

Talus' latest funding was a $***** Grant (prize money) round on Apr 02, 2025, with participation from 1 investor. Its primary sector is Oncology. In United States, the Oncology sector has seen $6.48B in funding in 2026 to date.

Where does Talus rank among its competitors?

Talus ranks 173rd amongst 3695 active competitors, of which 1229 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Talus?

Talus' top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Talus - 2026 Company Profile, Team, Funding & Competitors

Company Details

Provider of drug discovery platform for gene regulators. The company provides a functional proteomics platform MARMOT focused on studying full-length GRPs in an unmodified cellular environment. It allows the development of therapeutics against the disease-causing GRPs.

Website: www.talus.bio/
Social
Phone Number: +1 **********

Key Metrics

Founded Year

2020

Location

Seattle, United States

Stage

Seed

Total Funding

$19.8M in 8 rounds

Latest Funding Round

Grant (prize money), Apr 02, 2025, $*****

Post Money Valuation

$***** as on Feb 01, 2024

Investors

Y Combinator & 12 more

Ranked

173^rd among 3695 active competitors

Employee Count

28 as on Aug 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3418 more

View Talus' full profile

Talus is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
TALUS INC. CIN: 2169266 , United States, Active	Aug 12, 1988	-	-	-

Talus has raised a total funding of $19.8M over 8 rounds. Its first funding round was on 2020. Its latest funding round was a Grant (prize money) round on Apr 02, 2025 for $*****. 1 investor participated in its latest round. Talus has 13 institutional investors.

Here is the list of recent funding rounds of Talus:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 02, 2025	1349182	Grant (prize money)	8375503	6969217	6469686	1737189
Feb 21, 2025	4561930	Grant (prize money)	5423386	2560187	2829494	HHS
Jul 29, 2024	5173147	Seed	8790444	1096953	Two Bear Capital	Washington Research Foundation & 4 more

Access funding benchmarks and valuations. Sign up today!

View details of Talus's funding rounds and investors

The founders of Talus is Alex Federation. Alex Federation is the CEO of Talus.

Here are the details of Talus' key team members:

Alex Federation: Co-Founder & CEO of Talus and founder of 1 other company.
Contact Info: 1 email address

View details of Talus's Founder profiles and Board Members

Talus' employee count trend

Talus has 28 employees as of Aug 26. Here is Talus's employee count trend over the years:

Uncover Talus' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Talus include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Talus, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Leaps by Bayer, New Enterprise Associates ... & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
173rd	Talus 2020, Seattle (United States), Seed	Provider of drug discovery platform for gene regulators	$19.8M	FundersClub, Washington Research Foundation ... & 11 others	60/100